破伤风抗毒素临床应用及安全性研究进展

发布时间：2018-06-16 14:46

本文选题：破伤风抗毒素 + 临床应用　；参考：《中国药物警戒》2016年01期

【摘要】：目的了解破伤风抗毒素(tetanus antitoxin,TAT)的临床应用现状及其安全性研究进展,为开展上市后安全性评估提供参考。方法检索国内外研究TAT临床应用安全性相关的文献,对其进行归类分析研究。结果目前TAT在临床上主要应用于破伤风被动免疫和破伤风治疗;大量安全性研究显示,其皮试阳性率较高,主要与患者体质、药物因素、操作因素及其他原因造成假阳性过高有关。其不良反应主要有过敏性休克、血清病及其他类型不良反应。结论 TAT仍是国内为外伤患者预防破伤风的首选注射药物,建议在缶床应用中应重视过敏,注意观察,并尽快制定适合我国的破伤风预防指南和规范,促进合理用药。
[Abstract]:Objective to investigate the clinical application and safety of tetanus antitoxin TAT, and to provide a reference for post-market safety assessment. Methods the literature about clinical safety of tat was searched and classified. Results at present, tat is mainly used in the treatment of tetanus passive immunization and tetanus. A large number of safety studies show that the positive rate of skin test is high, which is mainly related to patients' physique and drug factors. Operating factors and other causes of false positive is too high. The main adverse reactions are anaphylactic shock, serological disease and other types of adverse reactions. Conclusion tat is still the first choice injection drug for the prevention of tetanus in China. It is suggested that attention should be paid to allergy and observation in the application of tetanus in Fou bed, and guidelines and norms for tetanus prevention suitable for our country should be drawn up as soon as possible to promote rational use of tetanus.
【作者单位】：江西省药品不良反应监测中心;
【分类号】：R978

【相似文献】